ASMB Stock — Assembly Biosciences Inc.: Cash, EV, Pipeline

Share price

$24.97

Market cap

$508.4M

Cash

$320.4M

Enterprise value

$188.0M

Balance sheet

Cash	$320.4M
Debt	$0.0M
Net cash	$320.4M
Enterprise value	$188.0M
Basic shares	19.9M shares
Fully diluted shares	33.2M shares
Fully diluted market cap	$829.8M
Cash per share	$16.10

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ASMB daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	ABI-6250	Phase 2	Chronic Hepatitis D Infection	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

GS-5366

Phase 1 · Active Modality: oral small molecule (long-acting)

Aliases ABI-5366, 5366

Target HSV helicase-primase

Partnerships Gilead Sciences: exercised option December 2025 to exclusively license the HPI program including 5366 and 1179; development now in Gilead's sole control; $100M upfront under 2023 Gilead collaboration

Indications

Recurrent genital herpes (Phase 1)

Status note Phase 1a/b complete; ready for Phase 2, but Gilead does not intend to develop 5366 further at this time (Gilead selected 1179 to advance).

GS-1179

Phase 1 · Active Modality: oral small molecule (long-acting, once-weekly)

Aliases ABI-1179, 1179

Target HSV helicase-primase

Partnerships Gilead Sciences: exercised option December 2025 to exclusively license the HPI program; development now in Gilead's sole control; $100M upfront under 2023 Gilead collaboration

Indications

Recurrent genital herpes (Phase 1)

Catalysts

— end of 2026

Status note Phase 1a/b complete; Gilead received clinical development plan in June 2026 and selected 1179 to advance. Possible combination evaluation with HIV PrEP under consideration.

ABI-6250

Phase 1 · Active Modality: oral small molecule (entry inhibitor)

Aliases 6250

Target NTCP (sodium taurocholate cotransporting polypeptide)

Indications

Chronic hepatitis delta virus (HDV) infection (Phase 2)
Primary biliary cholangitis / primary sclerosing cholangitis (Phase 2)

Catalysts

— Q4 2026
— Q1 2027

Status note Phase 2 preparation ongoing in both HDV and CLD; pre-IND meeting with FDA supported CLD program advancement. $115M financing expected to fund both Phase 2 studies.

ABI-4334

Phase 1 · Active Modality: oral small molecule

Aliases 4334

Target HBV capsid (capsid assembly modulator)

Indications

Chronic hepatitis B virus (HBV) (Phase 1)

Status note Positive Phase 1b topline reported. Company evaluating partnering opportunities via a structured process to further advance the program.

ABI-7272

Preclinical · Active Modality: oral small molecule

Aliases 7272

Target viral polymerase

Indications

Transplant-related herpesviruses (Stage not disclosed)

Status note Novel oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI); undergoing studies to enable a regulatory filing.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ABI-6250
Lead indication	Chronic Hepatitis D Infection
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07762027	Phase 2	Not yet recruiting	Sponsor	Assembly Biosciences	—	Chronic Hepatitis D Infection	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Assembly Biosciences on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	20,447	+500	0.03%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ASMB — Assembly Biosciences Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders